Suppr超能文献

8-羟基二丙胺基四氢萘诱导麻醉大鼠瞳孔扩张的药理学研究。

Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats.

作者信息

Yu Yongxin, Ramage Andrew G, Koss Michael C

机构信息

Department of Cell Biology, University of Oklahoma College of Medicine, Oklahoma City, OK 73190, USA.

出版信息

Eur J Pharmacol. 2004 Apr 12;489(3):207-13. doi: 10.1016/j.ejphar.2004.03.007.

Abstract

Serotonin (5-HT)(1A) receptor agonists have been reported to produce mydriasis in mice, and miosis in rabbits and humans. However, the underlying mechanisms for this action are unclear. This study was undertaken in an attempt to explore the mechanism by which 5-HT(1A) receptors are involved in the modulation of pupillary size in pentobarbital-anesthetized rats. Intravenous administration of the 5-HT(1A) receptor agonist, (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT; 0.003-3 mg/kg), elicited dose-dependent pupillary dilation, which was not affected by section of the preganglionic cervical sympathetic nerve. 8-OH-DPAT-elicited mydriatic responses were attenuated by the selective 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY 100635; 0.3-1 mg/kg, i.v.), as well as by the selective alpha(2)-adrenoceptor antagonist, (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-dechydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridine hydrochloride (RS 79948; 0.3 mg/kg, i.v.), but not by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg, i.v.). Mydriatic responses elicited by the alpha(2)-adrenoceptor agonist, guanabenz (0.003-0.3 mg/kg, i.v.), were not antagonized by WAY 100635 (0.3-1 mg/kg, i.v.). To determine whether central nervous system (CNS) 5-HT(1A) receptors, like alpha(2)-adrenoceptors, are involved in reflex mydriasis, voltage response curves of pupillary dilation were constructed by stimulation of the sciatic nerve in anesthetized rats. WAY 100635 (1 mg/kg, i.v.) did not antagonize the evoked reflex mydriasis, which, however, was blocked by RS 79948 (0.3 mg/kg, i.v.). Taken together, these results suggest that 8-OH-DPAT produces pupillary dilation in anesthetized rats by stimulating CNS 5-HT(1A) receptors, which in turn trigger the release of norepinephrine, presumably from the locus coeruleus. The latter reduces parasympathetic neuronal tone to the iris sphincter muscle by stimulation of postsynaptic alpha(2)-adrenoceptors within the Edinger-Westphal nucleus. Unlike alpha(2)-adrenoceptors, 5-HT(1A) receptors in the CNS do not mediate reflex mydriasis evoked by sciatic nerve stimulation.

摘要

据报道,血清素(5-羟色胺,5-HT)(1A)受体激动剂可使小鼠瞳孔散大,而使兔和人瞳孔缩小。然而,这种作用的潜在机制尚不清楚。本研究旨在探讨5-HT(1A)受体参与戊巴比妥麻醉大鼠瞳孔大小调节的机制。静脉注射5-HT(1A)受体激动剂(2R)-(+)-8-羟基-2-(二正丙基氨基)四氢萘氢溴酸盐(8-OH-DPAT;0.003 - 3 mg/kg)可引起剂量依赖性瞳孔散大,而节前颈交感神经切断对此无影响。8-OH-DPAT引起的散瞳反应可被选择性5-HT(1A)受体拮抗剂马来酸N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-N-2-吡啶基环己烷甲酰胺(WAY 100635;0.3 - 1 mg/kg,静脉注射)以及选择性α(2)-肾上腺素能受体拮抗剂盐酸(8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-脱氢-3-甲氧基-12-(乙基磺酰基)-6H-异喹啉并[2,1-g][1,6]萘啶(RS 79948;0.3 mg/kg,静脉注射)减弱,但不受选择性α(1)-肾上腺素能受体拮抗剂哌唑嗪(0.3 mg/kg,静脉注射)影响。α(2)-肾上腺素能受体激动剂胍那苄(0.003 - 0.3 mg/kg,静脉注射)引起的散瞳反应未被WAY 100635(0.3 - 1 mg/kg,静脉注射)拮抗。为了确定中枢神经系统(CNS)的5-HT(1A)受体是否像α(2)-肾上腺素能受体一样参与反射性散瞳,通过刺激麻醉大鼠的坐骨神经构建了瞳孔散大的电压反应曲线。WAY 100635(1 mg/kg,静脉注射)未拮抗诱发的反射性散瞳,然而,RS 79948(0.3 mg/kg,静脉注射)可阻断该反应。综上所述,这些结果表明8-OH-DPAT通过刺激中枢神经系统的5-HT(1A)受体使麻醉大鼠瞳孔散大,这反过来又触发去甲肾上腺素的释放,推测来自蓝斑核。后者通过刺激动眼神经背核内的突触后α(2)-肾上腺素能受体降低对虹膜括约肌的副交感神经张力。与α(2)-肾上腺素能受体不同,中枢神经系统中的5-HT(1A)受体不介导坐骨神经刺激诱发的反射性散瞳。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验